Novo Nordisk’s FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I rate NVO stock a Hold.
Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes
view original post
Novo Nordisk’s FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I rate NVO stock a Hold.